Prevention of progression of duodenal adenomas to cancer in patients with familial adenomatous polyposis.

Phase 3

Completed

• Conditions: Adenomatous polyposis coli; hereditary polyp disease; 10017934

• Registration Number: NL-OMON32335
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

-Patients with FAP with duodenal adenomas of Spigelman stage II and III, with an indication for duodenoscopy
-Patients with dyspeptic complaints with an indication for duodenoscopy, but without intestinal abnormalities.
- Age between18-70 years

Exclusion Criteria

- Patients with a history of a cardiovascular accident, gallstones, gastric or duodenal ulcers, a prior allergic reaction on NSAIDs or UDCA or disturbed renal (creatinine clearance < 50 ml/min.) or liver function (albumin < 25 g/l or Child-Pugh-score >= 10) will be excluded. No NSAIDs or UDCA may have been used during enrolment.
- Cardiac patients NYHA class II-IV.
- Age below 18 or above 70 years or incapable to sign informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified